Comerica Bank’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Comerica Bank’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,098	Closed	-$494K	–	2321
2020 Q2	$494K	Sell	3,098 -229	-7%	-$34.8K	﹤0.01%	1874
2020 Q1	$534K	Buy	3,327 +520	+19%	+$100K	﹤0.01%	1703
2019 Q4	$545K	Buy	+2,807	New	+$512K	﹤0.01%	1857

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Comerica Bank's RETA Position: Q3 2020 in Review

Comerica Bank sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 3,098 shares — an estimated $494K sold.

Comerica Bank first reported a position in RETA in Q4 2019 and held it in 3 quarters. The position peaked at $545K in Q4 2019. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

Comerica Bank reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
Comerica Bank sold 3,098 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $494K.
Comerica Bank first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 3 quarters.
Comerica Bank's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $545K in Q4 2019.
186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on Comerica Bank's 13F filing for Q3 2020, filed 30 Oct 2020.